Dystrophin Expressing Chimeric (DEC) Cell Therapy for Duchenne Muscular Dystrophy: A First-in-Human Study with Minimum 6 Months Follow-Up

Investigators presented a first-in-human study assessing the safety and efficacy of novel DEC cell therapy created by fusion of patient myoblasts with myoblasts of normal donor origin.